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1. INTRODUCTION 28 
 29 
Thyroid fine-needle aspiration cytology (FNAC) is one of the most performed medical 30 
procedures worldwide.1 It is used as a diagnostic test to separate benign thyroid nodules 31 
(colloidal and hyperplastic nodules) from thyroid malignancies, either primary (papillary 32 
thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid 33 
carcinoma (PDTC), anaplastic thyroid carcinoma (ATC)) or less often metastatic.2 The negative 34 
and positive predictive values (NPV and PPV) of this procedure in The Bethesda System for 35 
Reporting Thyroid Cytopathology (TBSRTC) are respectively 97% and 98% for the benign and 36 
malignant categories.3 Being a so frequent procedure, it is thus not rare in general 37 
cytopathology practice to encounter unusual lesions that pose diagnostic problems. The 38 
modern cytopathologist should also be aware of the clinical setting in which a lesion is 39 
aspirated and should interpret cytomorphology and ancillary tests results as a whole, in order 40 
to maintain high thyroid FNAC diagnostic accuracy.  41 
We report one of such difficult cases of thyroid FNAC that required integration of clinical, 42 
morphological and immunohistochemical findings to reach a correct diagnosis.  43 
 44 
 45 
2. CASE HISTORY 46 
 47 
A 54-year-old man with unremarkable past medical history presented with a rapidly 48 
growing right laterocervical nodule that, as he said, became palpable within a month. 49 
However, he also presented a pharyngeal discomfort with right shoulder pain for several 50 
months. On examination, the patient was in overall good physical condition. Cervical palpation 51 
confirmed a diffusely enlarged right thyroid lobe, as well as a right cervical mass measuring 52 
approximatively 5 cm. No sign of thyroid dysfunction was noted. 53 
A cervical ultrasound (US) confirmed the clinical appreciation and revealed not one but 54 
multiple and bilateral enlarged lymph nodes, all of them with highly suspicious features. This 55 
presentation suggested a primary thyroid malignant neoplasm with local metastatic spread. 56 
FNAC under ultrasound (US) guidance was then performed on the right thyroid lobe and the 57 
largest pathological lymph node. Following a cytopathological diagnosis of a high grade B-cell 58 
lymphoma, a lymph node biopsy was performed for precise subtyping and final diagnosis. 59 
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Meanwhile, a 18-FDG PET/CT revealed multiple pathological uptakes in the liver and spleen, 60 
as well as in the previously described cervical lesions. 61 
 62 
 63 
3. MATERIALS AND METHODS, RESULTS 64 
 65 
Cervical echography showed a 3.8x3.3x2.5 cm hypoechoic and hypovascular thyroid lesion 66 
with digitiform outline and heterogeneous content (Figure 1A, upper part), as well as multiple 67 
hypoechoic and partly ill-defined lymph nodes showing pathological vascularization and 68 
measuring up to 5.0x4.1x2.4 cm in the right neck  levels II, III and IV (Figure 1A, lower part).  69 
FNAC material aspirated from the thyroid lesion and the largest pathological lymph 70 
node showed similar cytomorphological features, consisting mainly of numerous malignant 71 
cells, isolated (Figure 1B) or forming loosely cohesive clusters on a background of cellular 72 
debris (Figure 1C). These cells had a high N/C ratio, a delicate cytoplasm that was often 73 
imperceptible on smears, and a large hyperchromatic nucleus with a granular chromatin and 74 
one or more nucleoli. Nuclear molding was observed. Focally, these cells were arranged in 75 
follicular or rosette-like structures sometimes surrounding a substance akin to colloid (Figure 76 
1D). The apparent cohesiveness of tumor cells, atypical mitoses and foci of tumor necrosis 77 
were easily identified on cell block preparation (Figure 1E). 78 
Based on a first morphological impression of a poorly differentiated malignant tumor, 79 
we performed an immunohistochemical panel from serial sections of the cell block, consisting 80 
of Thyroglobulin, TTF-1, Cytokeratins (CK) 8/18, Calcitonin, Pax-8, Chromogranin, 81 
Synaptophysin and S-100 (Table 1). Our initial differential diagnosis included a thyroid 82 
carcinoma (PDTC, ATC, MTC) metastatic to regional lymph nodes, and had to exclude 83 
secondary involvement of the thyroid gland and cervical lymph nodes by a metastatic process 84 
(in particular a melanoma and a neuroendocrine carcinoma, based on cytomorphology).  85 
All markers tested in this first round came back negative, apart from intense and 86 
diffuse nuclear positivity of Pax-8 (Polyclonal, Lubioscience) (Figure 1F). Our initially wide 87 
differential diagnosis was then mainly narrowed to ATC and PDTC as Pax-8 is typically positive 88 
in primary thyroid carcinoma. Loss of expression of epithelial markers such as cytokeratins 89 
and of thyroid differentiation markers (Thyroglobulin and TTF-1) are also well-known findings 90 
in ATC.  91 
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Abundant malignant cells and necrotic material were also supporting the hypothesis 92 
of ATC, despite the absence of clear-cut cell spindling or other heterologous elements. Pax-8 93 
expression is not restricted to thyroid malignancies, but can also be seen in thymic epithelial 94 
neoplasms (thymic carcinoma and carcinoma showing thymus-like differentiation – CASTLE) 95 
as well as in metastatic carcinoma mainly of Müllerian origin and kidney. Expression of 96 
cytokeratins 8/18 would however be expected at least focally in these carcinoma, as well as 97 
in Pax-8 negative carcinoma from other origins such as from the head and neck, lung and 98 
digestive system. Despite an expression of Pax-8 known to be restricted to carcinoma, and 99 
because of the particular cytomorphology of this tumor, additional antibodies were tested to 100 
strictly exclude a lymphoma. (Figure 1F, insets)(Table 1). To our surprise, a diffuse and strong 101 
expression of CD45 and CD20 by tumor cells was observed, thus raising some incertitude as 102 
for the expression of Pax-8 only by malignancies of epithelial lineage. Knowing that a subset 103 
of aggressive primary thyroid carcinoma shows an aberrant expression of CD204 and that CD45 104 
positivity has been rarely described in undifferentiated carcinoma5, a strong and diffuse 105 
expression of Pax-5 unequivocally confirmed the lymphomatous nature of the aspired tumor. 106 
Based on a preliminary cytopathological diagnosis of a high grade (large cell type) B-cell 107 
lymphoma, an excisional biopsy of a lymph node was advised for more precise subtyping. 108 
Biopsy material of the previously aspirated lymph node was sent to our laboratory few days 109 
later, and allowed to confirm a highly proliferating (ki-67 about 90%) diffuse large B-cell 110 
lymphoma with diffuse and strong expression of CD20 as well as of Pax-5 and polyclonal Pax-111 
8 (Figure 1G). As no translocation in MYC, BCL2 and BCL6 were identified by fluorescent in situ 112 
hybridization (FISH break apart probes, Zytovision, ref. Z-2090-200, Z-2192-200, Z-2177-200) 113 
the final diagnosis was that of a diffuse large B-cell lymphoma (DLBCL), NOS, infiltrating a 114 
cervical lymph node and the thyroid gland. After one cycle of a classic R-CHOP chemotherapy 115 
for a DLBCL, NOS stage IV-A, a partial response was observed on a 18-FDG PET/CT, in particular 116 
with a reduction of more than 70% of the volume of the largest laterocervical lymph node. 117 
After two additional cycles, a complete response with extinction of all initial uptakes was 118 







4. DISCUSSION 124 
 125 
 Undifferentiated thyroid carcinoma can lose expression of markers of epithelial and 126 
thyroid differentiation, while keeping a clear expression of Pax-8.6 Moreover, in presence of 127 
compatible cytological and clinical features, i.e. malignant cells and necrosis aspirated from a 128 
locally invasive tumor as assessed radiologically, further pathological investigations are 129 
sometimes unnecessary and a diagnosis of PDTC or ATC can be readily made.7, 8  130 
In the particular case of our patient, a combination of clinical and morphological 131 
aspects, along with the scientific curiosity of one of the authors (A. N.), were not fully 132 
compatible with our first cytomorphological impression and prevented a diagnosis of PDTC or 133 
ATC. 134 
Clinically, ATC usually present as a thyroid mass with wide extrathyroidal extension.8 135 
Laterocervial lymph node metastasis are not so frequent. Immediate symptoms related to 136 
brisk extrathyroidal infiltration often lead to a high clinical suspicion of ATC. In our case, the 137 
patient symptoms appeared progressively and the US examination of the thyroid and neck 138 
were not pathognomonic of an ATC. However, absence of cytokeratin, Thyroglobulin and TTF-139 
1 expression coupled with retained Pax-8 expression were still favoring a diagnosis of ATC.9 140 
Retrospectively, additional cytokeratins could have been tested to decrease the possibility to 141 
be dealing with an ATC. Cytokeratin 7 alone or as part of a cytokeratin cocktail such as AE1/AE3 142 
or MNF-116 would have been an appropriate addition, as it is reported that CK7 and CK18 are 143 
expressed in 84% and 80% of ATC, respectively.10 Moreover, use of Pax-8 is encouraged in 144 
undifferentiated thyroid tumors with limited or no expression of TTF-1 and cytokeratins.9 145 
Clinically, a well-delineated thyroid nodule associated with regional metastatic lymph node 146 
would be more consistent with a metastatic PTC or PDTC. The first hypothesis was excluded 147 
by the absence of typical PTC nuclei and by the absence of cytokeratin and TTF-1 expression. 148 
As for PDTC, absence of papillary or follicular architecture, severe crowding, single cells, and 149 
high nuclear/cytoplasmic ratio were the most predictive diagnostic features.11 Despite partly 150 
compatible cytomorphology, the absence of cytokeratin, Thyroglobulin and TTF-1 expression 151 
is atypical for a PDTC, as it is known to show diffuse expression of TTF-1 and at least to retain 152 
some expression of Thyroglobulin.9, 12  153 
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Trying to find an explanation in the literature for the expression of Pax-8 in our case, 154 
apart from numerous articles describing the well-known expression of this protein by tumors 155 
of genito-urinary origin, we identified some interesting papers.  156 
A first study showed that the N-terminal regions of Pax-8 and Pax-5 have a high 157 
sequence homology, and consequently, that polyclonal Pax-8 antibody can cross-react with 158 
Pax-5 N-terminal epitope present in reactive and neoplastic B-cells.13 This was further 159 
demonstrated by the absence of Pax-8 mRNA in the B-cell lines studied. Knowing of the 160 
possible pitfalls of CD20 and CD45 expression in poorly differentiated epithelial malignancies 161 
reported in the cervical region necessitated additional specific B-cell markers.4,5,14 The 162 
demonstration of a diffuse and strong nuclear expression of Pax-5 in tumor cells using a 163 
monoclonal antibody (1EW, Leica biosystems) in cytological (cytoblock from the FNAC) and 164 
histological (lymph node biopsy) materials confirmed the hypothesis of a polyclonal-Pax-8-165 
antibody-to-Pax-5-epitope cross-reaction. Eventually, a monoclonal Pax-8 (API438AA, Biocare 166 
Medical, Table 1) was tested in both materials in another laboratory, and as expected, came 167 
back entirely negative.  168 
Few case reports documenting similar cross-reactivity with polyclonal Pax-8 antibody 169 
in various adverse situations were also found, one of them describing a patient known for a 170 
metastatic renal cell carcinoma and a Pax-8 positive adrenal gland lesion that turned out to 171 
be a B-cell lymphoma in lieu of a Pax-8 positive metastasis from his kidney cancer.15 Common 172 
to these challenging cases is the knowledge of possible antibody cross-reactivity and thus the 173 
use of extended immunohistochemistry panels in poorly differentiated tumors.  174 
Concerning makers of lymphoid lineage, as already mentioned, there are some known 175 
overlapping stainings among lymphoma and carcinoma that can be troublesome in some 176 
situations4,5. CD20 is expressed in 14.8% and 8.2% of the encapsulated and infiltrative variants 177 
of PTC, respectively, as well as in metastatic PTC.14 CD45 can even be exceptionally expressed 178 
by undifferentiated carcinoma. As for Pax-5, apart from positivity reported in few Merkel cell 179 
carcinoma16 (along with co-expression of TTF-1), the monoclonal Pax-5 antibody we tested 180 
seems to be the most discriminant marker in the differential diagnosis between an ATC and a 181 
high grade B-cell lymphoma.  182 
 183 
In conclusion, we would like to draw the attention of the reader on certain aspects of 184 
this case that we found interesting. Identifying the origin and nature of a poorly differentiated 185 
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tumor cannot rely only on immunohistochemical panels and has to be considered along with 186 
detailed clinical information and an appropriate morphological analysis. Polyclonal antibodies 187 
are easy to produce and thus cheaper, but they’re less specific than their monoclonal 188 
counterparts and thus have to be interpreted carefully, above all in situations like the one we 189 
presented where a single antibody could be responsible of an entire diagnosis. Inner and outer 190 
controls are of prime importance in immunohistochemistry: back to the polyclonal Pax-8 191 
staining we performed, a clue to cross-reactivity can be appreciated as it is possible to identify 192 
Pax-8 positive small round cells that are actually non-neoplastic B-cells. Finally, in our case, it 193 
has been of prime importance to avoid misdiagnosing an ATC, because the patient would have 194 
been treatable surgically and would have thus received a wrong and delayed treatment.  195 
 196 
  197 
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5. FIGURES LEGENDS 198 
 199 
Figure 1. Ultrasound aspects of the thyroid nodule and a laterocervical lymph node, and 200 
cytopathological fine-needle aspiration features. 1A: upper part: transversal view of the right 201 
lobe of the thyroid gland centered on a 3,8x3,3x2,5cm hypoechoic and hypovascular lesion 202 
with digitiform outline and heterogeneous content (arrowheads: thyroid lesion; SCM: sterno-203 
cleido-mastoid muscle; C: carotid artery); lower part: right level III pathological lymph node 204 
measuring 5.0x4.1x2.4 cm. 1B, 1C: isolated and loosely cohesive groups of malignant cells on 205 
a necrotic and hemorrhagic background. Nuclei were hyperchromatic, irregular in shape and 206 
size, partly with an evident nucleoli. Cytoplasm and cell membrane were often imperceptible. 207 
(Papanicolaou stain, background 200x, inset 400x). 1D: follicular and rosette-like structures of 208 
malignant cells encircling a substance akin to colloid (Papanicolaou stain, 400x). 1E: cellblock 209 
preparation with apparently cohesive malignant cells, partly atypical mitosis and foci of 210 
cellular necrosis (H&E stain, background 200x, inset 400x).  1F: cellblock preparation with 211 
diffuse and intense nuclear positivity of polyclonal Pax-8 (immunostaining, background 200x); 212 
insets show intense and diffuse expression of CD45 (immunostaining, left inset, 200x) and 213 
CD20 (immunostaining, right inset, 200x) thus supporting the final cytological diagnosis of a 214 
high grade B-cell lymphoma. 1G: material from the resected lymph node showing malignant 215 
cells with a diffuse and strong expression of CD20 (upper right corner, immunostaining, 40x), 216 
Pax-5 (lower right corner, immunostaining, 40x), polyclonal Pax-8 (upper left corner, 217 
immunostaining, 200x) and monoclonal Pax-8 (lower left corner, immunostaining, 200x).  218 
 219 
Figure 2. Immunohistochemical panels performed on cytological and biopsy materials. 2A: 220 
on cellblock preparation, Thyroglobulin (left), Cytokeratins 8/18 (middle) and TTF-1 (right) 221 
were clearly negative (immunostainings, 100x). 2B: on the contrary, on the same material, 222 
polyclonal Pax-8 showed diffuse and intense nuclear positivity (immunostaining, background 223 
200x, inset 400x), narrowing down the differential diagnosis to primary or metastatic Pax-8 224 
positive carcinoma. 2C: additional markers to rule out a lymphoma during diagnostic process: 225 
CD45, Pax-5, CD20 (immunostainings, 100x) were diffusely positive, thus supporting the final 226 
cytological diagnosis of a high grade B-cell lymphoma. 2D: tumor cell morphology from the 227 
resected lymph node was identical to that observed on the cellblock (H&E, background 200x). 228 
Malignant cells expressed diffusely and strongly CD20 (2D, upper inset, immunostaining, 40x), 229 
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Pax-5 (2D, lower inset, immunostaining, 40x) and polyclonal Pax-8 (2E, immunostaining, 230 
background 40x; inset 200x).  231 
 232 
 233 
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